Aktis Oncology (AKTS) – What Are Investment Firms Thinking About This Stock?

Shares of Aktis Oncology (NASDAQ:AKTS) have been assigned a consensus recommendation of “Moderate Buy” from the eleven research firms that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $35.62.

AKTS has been the subject of several research analyst reports. BMO Capital Markets assumed coverage on shares of Aktis Oncology in a research note on Tuesday, August 18th. They set an “outperform” rating and a $37.00 price target for the company. Wall Street Zen lowered Aktis Oncology from a “hold” rating to a “sell” rating in a report on Saturday, July 25th. Weiss Ratings cut Aktis Oncology from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, October 2nd. Wedbush restated an “outperform” rating and set a $35.00 price objective on shares of Aktis Oncology in a report on Friday, October 2nd. Finally, Oppenheimer began coverage on Aktis Oncology in a report on Wednesday, September 9th. They issued an “outperform” rating and a $40.00 price objective on the stock.

Aktis Oncology Price Performance

AKTS stock opened at $15.11 on Tuesday. The company has a market capitalization of $812.16 million and a PE ratio of -18.43. Aktis Oncology has a 12 month low of $14.72 and a 12 month high of $34.19. The firm’s 50-day moving average is $22.10 and its 200 day moving average is $22.10.

Aktis Oncology (NASDAQ:AKTS) last released its quarterly earnings data on Thursday, August 13th. The technology company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.01). The business had revenue of $3.38 million for the quarter, compared to the consensus estimate of $2.70 million. Sell-side analysts forecast that Aktis Oncology will post -1.84 EPS for the current fiscal year.

Institutional Investors Weigh In On Aktis Oncology

A number of hedge funds have recently modified their holdings of AKTS. State of Wyoming purchased a new position in shares of Aktis Oncology in the second quarter worth about $32,000. GK Wealth Management LLC acquired a new position in Aktis Oncology during the third quarter worth about $26,000. AXQ Capital LP acquired a new position in Aktis Oncology during the second quarter worth about $226,000. Susquehanna International Group LLP purchased a new stake in Aktis Oncology during the 2nd quarter valued at about $278,000. Finally, Deutsche Bank AG grew its stake in Aktis Oncology by 49.3% during the 2nd quarter. Deutsche Bank AG now owns 21,022 shares of the technology company’s stock valued at $678,000 after acquiring an additional 6,942 shares in the last quarter. 28.84% of the stock is currently owned by institutional investors and hedge funds.

Aktis Oncology Company Profile

Aktis Oncology, Inc is a clinical-stage biopharmaceutical company developing targeted alpha therapies for the treatment of cancer. Its research is focused on creating therapies designed to selectively deliver alpha-particle radiation to tumor cells while limiting exposure to surrounding healthy tissue.

The company’s platform uses proprietary tumor-targeting molecules, including engineered miniproteins, to bind specific targets found on cancer cells and transport radioactive payloads to tumors.